Plant Name: Olea europaea
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| PTPN1; PTPN2; CDC25B; | |
| PLA2G1B; RECQL; TDP1; MIF; GLO1; ALOX12; AKR1B1; HSD17B10; AKR1B10; NOX4; ALOX15; TNKS; PARP1; TNKS2; CD38; POLB; | |
| TRPA1; | |
| GSK3B; FLT3; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA3; CA5B; CA5A; CA4; CA6; | |
| NR1H4; | |
| ESR2; | |
| ALOX5; MAOA; XDH; | |
| KDM4E; | |
| MMP9; MMP12; MMP2; | |
| HIF1A; TP53; | |
| ABCG2; | |
| L3MBTL1; SMN1;SMN2; | |
| LMNA; APP; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 7.987E-08 | 4.577E-05 | CA2, CA7, CD38, HIF1A, MIF, NR1H4, PARP1, PLA2G1B, TNKS, TNKS2, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.460E-07 | 7.227E-05 | AKR1B1, AKR1B10, ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, GSK3B, HSD17B10, KDM4E, MAOA, NOX4, XDH |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.409E-07 | 1.485E-04 | ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, XDH |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 7.316E-07 | 2.747E-04 | APP, CA2, CA9, CD38, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4, PARP1, TP53, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.748E-06 | 5.636E-04 | ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.585E-06 | 7.605E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 3.318E-06 | 9.384E-04 | CD38, MIF, PARP1, TNKS, TNKS2, TRPA1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.444E-06 | 9.615E-04 | CA2, CA7, HIF1A, NR1H4, PLA2G1B, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.642E-26 | 1.011E-21 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.177E-06 | 1.564E-03 | AKR1B1, AKR1B10, APP, CYP1A1, CYP1A2, CYP1B1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 7.961E-06 | 1.882E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 7.961E-06 | 1.882E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.036E-06 | 1.882E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 8.421E-06 | 1.951E-03 | CD38, CYP1A1, HIF1A, LMNA, MMP2, NOX4, TP53 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.178E-05 | 2.515E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, HIF1A, PLA2G1B, TP53, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.192E-05 | 2.519E-03 | ALOX12, ALOX15, ALOX5 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.266E-05 | 2.600E-03 | HIF1A, MMP12, MMP2, MMP9, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.674E-05 | 3.283E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.384E-05 | 4.326E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 2.384E-05 | 4.326E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.384E-05 | 4.326E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.384E-05 | 4.326E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 2.384E-05 | 4.326E-03 | GPBAR1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.802E-05 | 4.810E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.802E-05 | 4.810E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 2.896E-05 | 4.888E-03 | ABCG2, APP, CA2, CA7, CD38, HIF1A, PLA2G1B, TP53, TRPA1 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.368E-05 | 5.599E-03 | AKR1B1, ALOX12, CD38, CDC25B, FLT3, HIF1A, MIF, MMP12, MMP2, MMP9, PLA2G1B |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.421E-05 | 5.644E-03 | ABCG2, APP, CD38, ESR2, FLT3, L3MBTL1, MIF, MMP9, PARP1, SMN1, SMN2, TP53, TRPA1, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.716E-05 | 5.993E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.716E-05 | 5.993E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 3.796E-05 | 6.078E-03 | ABCG2, AKR1B1, CA3, CA9, CD38, CYP1A1, CYP1B1, POLB, TP53, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 4.759E-05 | 7.267E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 4.759E-05 | 7.267E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.759E-05 | 7.267E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0050730; regulation of peptidyl-tyrosine phosphorylation | 4.871E-05 | 7.315E-03 | APP, FLT3, MIF, PTPN1, PTPN2, TP53 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 5.359E-05 | 7.871E-03 | CD38, HIF1A, MIF, MMP12, NR1H4, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 5.422E-05 | 7.871E-03 | PARP1, TNKS, TNKS2 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 5.534E-05 | 7.980E-03 | MMP12, MMP2, MMP9, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 6.087E-05 | 8.607E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 6.087E-05 | 8.607E-03 | APP, GSK3B, PARP1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.455E-19 | 1.782E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.539E-18 | 1.164E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.161E-15 | 5.228E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, GLO1, L3MBTL1, MMP12, MMP2, MMP9, NR1H4, PARP1, PTPN1, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.859E-25 | 3.488E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.345E-06 | 2.651E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.401E-05 | 5.697E-04 | APP; MAOA; ALOX5; ALOX15; ALOX12 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.536E-05 | 7.735E-04 | PLA2G1B; ALOX5; ALOX15; ALOX12 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.106E-04 | 1.928E-03 | AKR1B10; PLA2G1B; MAOA; ALOX5; CYP1A2; ALOX15; CYP1A1; CD38; AKR1B1; ALOX12; HSD17B10; XDH |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.835E-05 | 1.502E-03 | PLA2G1B; CYP1A2; ALOX15 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.948E-04 | 2.971E-03 | MMP2; MMP9; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.513E-04 | 8.332E-03 | GSK3B; FLT3; MMP2; HIF1A; TP53; MMP9 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.520E-04 | 4.771E-03 | ALOX5; CYP1A1; CYP1B1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.323E-04 | 8.462E-03 | FLT3; TP53; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.455E-04 | 6.656E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.345E-03 | 1.507E-02 | MMP2; TP53; HIF1A; MMP9 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.068E-03 | 8.687E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 9.853E-04 | 8.587E-03 | CA2; NR1H4; ABCG2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.561E-03 | 1.562E-02 | MMP2; MMP9; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.495E-03 | 1.140E-02 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.347E-03 | 1.507E-02 | CA2; PLA2G1B; CD38 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.201E-03 | 2.050E-02 | GSK3B; TP53; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.753E-03 | 2.942E-02 | PARP1; LMNA; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.974E-03 | 3.667E-02 | CYP1B1; TP53; MMP9; CDC25B |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 4.825E-03 | 2.180E-02 | GSK3B; TP53; CDC25B |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.110E-02 | 4.231E-02 | APP; GSK3B; HSD17B10 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.335E-02 | 4.655E-02 | FLT3; TP53; MMP9 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.016E-03 | 3.667E-02 | GSK3B; TP53 |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 9.834E-04 | 8.587E-03 | MAOA; MIF |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.264E-02 | 4.534E-02 | GSK3B; TP53 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.149E-02 | 4.249E-02 | AKR1B10; AKR1B1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.074E-03 | 1.786E-02 | AKR1B10; AKR1B1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.004E-02 | 3.953E-02 | GSK3B; TP53 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 4.168E-03 | 2.050E-02 | MAOA; MIF |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.810E-03 | 1.299E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.386E-05 | 1.502E-03 | CYP1A2; XDH |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.383E-02 | 4.685E-02 | CYP1A2; CYP1A1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 3.493E-03 | 1.937E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 3.712E-03 | 1.969E-02 | POLB; PARP1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 4.406E-03 | 2.067E-02 | AKR1B10; AKR1B1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; MMP12; PLA2G1B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| NA: NA | Edema | NA | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MIF; MMP12; PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; PLA2G1B |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| C00-D49: Neoplasms | Melanoma | C43 | PARP1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | PARP1; MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | TRPA1 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; PLA2G1B |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Cancer | C00-C96 | GSK3B; HIF1A; TP53; CA1; FLT3; FLT3; CA9; MMP9; PARP1; MMP2; CD38; CDC25B; APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAOA; APP |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1; PLA2G1B |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; MMP9; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |